Nebula Research & Development LLC Cytokinetics Inc Transaction History
Nebula Research & Development LLC
- $1.17 Trillion
- Q2 2025
A detailed history of Nebula Research & Development LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Nebula Research & Development LLC holds 12,411 shares of CYTK stock, worth $824,586. This represents 0.03% of its overall portfolio holdings.
Number of Shares
12,411
Previous 12,165
2.02%
Holding current value
$824,586
Previous $489 Million
16.13%
% of portfolio
0.03%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
446Shares Held
135MCall Options Held
5.25MPut Options Held
1.18M-
T. Rowe Price Investment Management, Inc. Baltimore, MD19.1MShares$1.27 Billion0.64% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$975 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$788 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.41MShares$492 Million0.07% of portfolio
-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct6MShares$399 Million0.17% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $6.25B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...